Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Almirall S.A. is conducting a study titled ‘Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting – Light Version.’ The study aims to explore the connection between clinical symptoms and quality of life in patients with moderate to severe plaque psoriasis treated with Tildrakizumab, a drug administered in routine clinical settings.
The intervention being tested is Tildrakizumab, a drug designed to treat moderate to severe plaque psoriasis. It is used in real-world clinical practice to assess its impact on patient wellbeing and quality of life.
This observational study follows a cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on observing the outcomes of patients receiving the drug in a real-world setting.
The study began on April 4, 2024, with the primary completion date yet to be announced. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence Almirall’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the psoriasis treatment sector. Investors should also consider the competitive landscape, as advancements in psoriasis treatments are ongoing across the industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.